Objective: To construct a model to predict the risk of gestational diabetes mellitus (GDM) based on a nomogram and verify it.

Methods: Data from 182 patients with GDM treated in Xi'an International Medical Center Hospital from January 2018 to May 2021 were retrospectively analyzed. A total of 491 normal parturients who underwent physical examination in Xi'an International Medical Center Hospital during the same period were selected as controls. With a ratio of 7:3, patients with GDM were divided into a training group (n=128) and a verification (n=54) group, and 491 normal parturients were divided into a training control group (n=344) and a verification control group (n=147). Clinical data were collected, and risk factors for GDM were analyzed by logistic regression. R language was used to construct a prognostic prediction nomogram model for GDM, and a receiver operating characteristic curve was employed to evaluate the accuracy of this nomogram model in predicting the prognosis of GDM.

Results: Univariate analysis revealed that age, body mass index (BMI), family history of diabetes, hemoglobin, triglycerides, serum ferritin, and fasting blood glucose in the first trimester were different between the training group and the training control group (P<0.05). Multivariate analysis revealed that age, BMI, hemoglobin, triglycerides, serum ferritin, and fasting blood glucose in the first trimester were independent risk factors for GDM (P<0.05). Based on a logistic regression equation, the risk formula was -5.971 + 1.054 * age + 1.133 * BMI + 1.763 * hemoglobin + 1.260 * triglycerides + 3.041 * serum ferritin + 1.756 * fasting blood glucose in the first trimester. The area under the curve for predicting the risk of GDM in the training group was 0.920, and that of the validation group was 0.753.

Conclusion: Age, BMI, hemoglobin, serum ferritin, and fasting blood glucose in the first trimester are risk factors for GDM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006798PMC

Publication Analysis

Top Keywords

control group
12
gestational diabetes
8
based nomogram
8
patients gdm
8
xi'an international
8
international medical
8
medical center
8
center hospital
8
491 normal
8
normal parturients
8

Similar Publications

Background: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.

Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.

View Article and Find Full Text PDF

Background: Studies suggest a potential link between stroke and Alzheimer's disease wherein stroke may serve as a trigger for the onset or acceleration of Alzheimer's pathogenesis as damage to the brain's blood vessels may lead to the accumulation of amyloid beta protein which is a hallmark of Alzheimer's disease. Recent research has shown that stroke treatment may hold the key to treating Alzheimer's disease. The anti-inflammatory potentials of Cholinergic signaling are a novel therapeutic target in memory decline associated with Alzheimer's.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.

Background: Donepezil, an acetylcholinesterase inhibitor (AChEI), is an FDA-approved drug to treat these neurodegenerative diseases, e.g., Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!